RxDoctor Payments Data

Ashley Steinberg, MD

Plastic and Reconstructive Surgery · Bellaire, TXNPI 1730529728

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $65,000 of the $101,676 with a category attached, or 63.9%. Sientra, Inc. accounts for 69.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $67,496 and has fallen 78.4% since, to $14,603 in 2025. Among plastic and reconstructive surgery clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$101,676in general payments, 2019–2025

Across 536 payments — averaging $189.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sientra, Inc.$70K
  • AbbVie$23K
  • Motiva USA, LLC$2K
  • Davol Inc.$1K
  • Revance Therapeutics, Inc.$945
  • Integra Lifesciences Corporation$788
  • plus $4K from 15 others
$35,750in research payments, 2019–2025

Across 1 payment — averaging $35,750 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sientra, Inc.$36K

What the payments were for

  • Consulting fees$10,20010%
  • Speaking & faculty fees$65,00064%
  • Travel & lodging$9,76510%
  • Food & beverage$16,28916%
  • Education$80%
  • Gifts$870%
  • Other$3260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$101,676 in reported general payments places this provider in the 95th percentile of 378 plastic and reconstructive surgery providers in Texas.

See all plastic and reconstructive surgery providers in Texas

Medicare billing

Part B allowed, 2024
$6,280
Medicare patients
12
Services billed
17

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Doxycycline Hyclate11$55

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Bellaire

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →